Discontinued — last reported Q1 '26
Adempas — Sales
Merck & Co. Adempas — Sales decreased by 4.9% to $78.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.7%, from $68.00M to $78.00M. Over 3 years (FY 2021 to FY 2025), Adempas — Sales shows a downward trend with a -14.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand, successful commercial execution, or effective pricing strategies, while a decrease may signal market saturation, increased competition, or loss of exclusivity.
Detailed definition
This metric measures the total gross revenue generated from the sale of the Adempas product line within a specific repor...
Peer comparison
Comparable to product-specific revenue reporting found in the segment disclosures of major global pharmaceutical and biotechnology firms.
mrk_segment_adempas_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $148.00M | $118.00M | $128.00M | $122.00M | $126.00M | $114.00M | $114.00M | $118.00M | $130.00M | $65.00M | $70.00M | $72.00M | $72.00M | $73.00M | $68.00M | $80.00M | $82.00M | $82.00M | $78.00M |
| QoQ Change | — | -20.3% | +8.5% | -4.7% | +3.3% | -9.5% | +0.0% | +3.5% | +10.2% | -50.0% | +7.7% | +2.9% | +0.0% | +1.4% | -6.8% | +17.6% | +2.5% | +0.0% | -4.9% |
| YoY Change | — | — | — | — | -14.9% | -3.4% | -10.9% | -3.3% | +3.2% | -43.0% | -40.7% | -44.6% | +10.8% | — | -2.9% | +11.1% | +13.9% | +12.3% | +14.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s adempas — sales?
- Merck & Co. (MRK) reported adempas — sales of $78.00M in Q1 2026.
- How has Merck & Co.'s adempas — sales changed year-over-year?
- Merck & Co.'s adempas — sales increased by 14.7% year-over-year, from $68.00M to $78.00M.
- What is the long-term trend for Merck & Co.'s adempas — sales?
- Over 3 years (2021 to 2025), Merck & Co.'s adempas — sales has grown at a -14.8% compound annual growth rate (CAGR), from $504.00M to $312.00M.
- What does adempas — sales mean?
- The total revenue generated from the sale of the Adempas product.